Leflunomid v léčbě psoriatické artritidy

Číslo: 6 / 2009 (Obsah)
Rubrika: Farmakoterapeutické postupy
Obor: Revmatologie
Autoři: MUDr. Jiří Štolfa
Autoři - působiště: Revmatologický ústav, Praha
Citace: 1 Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003; 4:441–7 2 Blumberg BS, Bunim JJ, Calkins E, et al. ARA nomenclature and classification of arthritis and rheumatism (tentative). Arthritis Rheum 1964;26:93–7. 3 Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868–72. 4 Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64(Suppl 2):ii26–9. 5 National Psoriasis Foundation. New research shows 1 million US adults suffer from psoriatic arthritis: others may be at risk but not know it. Portland, (OR);NPF Press Release;May 13, 2002.; 2002 URL; http//www.psoriasis.org/release 2002.psasurvey.htm 6 Black RL, O’Brien WM, Van Scott EJ, et al. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. J Am Med Assoc 1964;189:743–7. 7 Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005;64:74–7. 8 Kaltwasser JP, Behrens F. Leflunomide: Long-term clinical experience and new uses. Exp Opin Pharmacother 2005; 6:787–801 9 Cutolo M, Sulli A, Ghiorzo P, et al. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62:297–302. 10 Siemasko KF, Chong AS, Williams JW, et al. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996;61(4):635–42. 11 Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000;43:1820–30. 12 Fox RI, Herrmann ML, Frangou CG, et al. How does leflunomide modulate the immune response in rheumatoid arthritis? Bio Drugs 1999;12:301–15. 13 McIlnnes IB. Cytokine targeting in psoriasis and psoriatic arthritis: beyond TNF-alpha. Ernst Schering Res Found Workshop 2006;56:29–44. 14 Gonzáles-Alvaro I, Ortiz AM, Domíngues-Jiménez C, et al. Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis 2009;68:1644–50. 15 Sharp JT, Strand V, Leungh H, et al. Treatment with leflunomide slows rediographic progression of rheumatoid arthritis: results from three randomized clinical trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000;43:495–505. 16 Aventis Pharmaceuticals, Inc. ARAVA® Tablets (leflunomide) prescribing information (2004). 17 Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002;41(6):421–30. 18 Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999;58:1137–64. 19 Liang GC,Barr WG. Open trial od leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol 2001;7:366–70. 20 Reich K, Hummel KM, Beckmann I, et al. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol 2002;146:335–6. 21 Tlacuilo-Parra JA, Guevara-Gutierrez E, Rodriguez-Castellanos MA, et al. Leflunomide in the treatment of psoriasis: results of a phase II open trial. Br J Dermatol 2004;150:970–6. 22 Thami GP, Garg G. Leflunomide in psoriasis and psoriatic arthritis: a preliminary study. Arch Dermatol 2004;140:1288–9. 23 Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939–50. 24 van der Heijde D, Kalden J, Scott D, et al. Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann Rheum Dis 2004;63:737–9. 25 Cuchacovich M, Soto L. Leflunomide decreases joint erosions and induces reparative changes in a patient with psoriatic arthritis. Ann Rheum Dis 2002;61:942–3. 26 Tlacuilo-Parra JA, Guevara-Gutierrez E, Rodriguez-Castellanos MA, et al. Leflunomide in the treatment of psoriasis: results of a phase II open trial. Br J Dermatol 2004;150:970–6. 27 Cannon GW, Holden WL, Juhaeri J, et al. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol 2004;31:1906–11. 28 Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008;67:855–9.

Celý článek je dostupný jen pro předplatitele časopisu


Přihlášení

 

Předplatné

Více o předplatném

 
 
 
Jste odborný pracovník ve zdravotnictví?
Jsem odborníkem ve smyslu §2a Zákona č. 40/1995 Sb., o regulaci reklamy, ve znění pozdějších předpisů, čili jsem osobou oprávněnou předepisovat léčivé přípravky nebo osobou vydávat léčivé přípravky.

Potvrzuji, že jsem se seznámil/a s definicí odborník
dle zákona č. 40/1995 Sb.
Potvrzuji, že jsem se seznámil/a s riziky, jimž se jiná osoba než odborník vystavuje, vstoupí-li na stránky určené pro odborníky